Giripladib, also known as PLX-695, is a cPLA2 specific inhibitor. Treatment with PLA-695 attenuated radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells. PLA-695 in combination with irradiation (IR) significantly reduced migration and proliferation in endothelial cells (HUVEC & bEND3) and induced cell death and attenuated invasion by tumor cells (LLC &A549). In a heterotopic tumor model, the combination of PLA-695 and radiation delayed growth in both LLC and A549 tumors. LLC and A549 tumors treated with a combination of PLA-695 and radiation displayed reduced tumor vasculature.
MedKoo Cat#: 206594
Name: Giripladib
CAS#: 865200-20-0
Chemical Formula: C41H36ClF3N2O4S
Exact Mass: 744.2036
Molecular Weight: 745.25
Elemental Analysis: C, 66.08; H, 4.87; Cl, 4.76; F, 7.65; N, 3.76; O, 8.59; S, 4.30
The following data is based on the product molecular weight 745.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
